Antimicrobial-resistant infections are expensive to treat and place an economic burden on families and health systems.

Key Evidence: The US CDC estimates that antibiotic resistant pneumococcal infections in the US add $96 million to the costs of treatment each year.

Key Evidence: The costs and health effects of treating typhoid might soon increase dramatically, since the bacteria that causes typhoid is becoming increasingly resistant to the most effective oral antimicrobial drugs, thus requiring treatment with more expensive intravenous antibiotics which may result in more frequent hospitalizations for suspected typhoid cases.